Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Justine GantzerGuillaume DavidsonBujamin VokshiNoëlle WeingertnerAntoine BougoüinMarco MoreiraVéronique LindnerGuillaume LacroixCéline MascauxMarie-Pierre ChenardFrançois BertucciIrwin DavidsonJean-Emmanuel KurtzCatherine Sautès-FridmanWolf H FridmanGabriel G MaloufPublished in: The oncologist (2022)
SMARCA4-UT mainly have an immune desert TME with limited efficacy to ICI. TME of SMARCA4-driven tumors varies according to the cell of origin questioning the interplay between BAF alterations, cell ontogeny and immunity.